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Open access under the ElObjective: Nasopharyngeal carcinoma (NPC) is rare in western countries albeit affected by common and
unrelated phenomena: smoking less in men, more in women and immigration from China and North
Africa. We studied trends in NPC incidence, tumour morphology, survival and mortality in order to assess
progress against this cancer.
Materials and methods: A trend analysis was performed with nationwide incidence and survival data
(from The Netherlands Cancer registry in 1989–2009), followed by analysis of mortality (data from
Statistics Netherlands) covering the period 1970–2009, and calculating estimated percentages of change
(EAPC) in both. According to the WHO classiﬁcation we distinguished keratinizing SCC (WHO-I),
differentiated (WHO-IIA) and undifferentiated (WHO-IIB) non-keratinizing carcinoma.
Results: NPC incidence signiﬁcantly decreased since 1989, especially in males (EAPC 1989–2009: 1.3;
95% CI: 2.5, 0.2) and in patients with keratinizing SCC (WHO-I) (EAPC: 3.6; 95% CI: 5.3, 1.8).
By contrast, the incidence of differentiated non-keratinizing tumours (WHO-IIA) signiﬁcantly increased
in the same period (EAPC: 9.6; 95% CI: 5.6, 13.5). One- and three-year relative survival, as an indicator
of disease-speciﬁc survival increased slightly from 79% to 81% and from 57% to 65% since 1989. NPC
mortality signiﬁcantly decreased since 1970 (EAPC: 1.2; 95% CI: 1.8, 0.5) and more pronounced since
1989 (EAPC: 3.0; 95% CI: 4.3, 1.6).
Conclusion: During the past two decades, the incidence of NPC in The Netherlands decreased mainly by
less keratinizing, supposedly smoking-related NPC (WHO-I). However, the incidence of non-keratinizing
NPC (WHO-IIA, B) increased, most likely due to EBV infection and thus related to higher immigration
levels of people from high-incidence areas.
 2012 Elsevier Ltd. Open access under the Elsevier OA license. Introduction
Nasopharyngeal carcinoma (NPC) has a substantial geographic
and demographic variation. In western countries, NPC is an orphan
disease with incidence rates below one per 100,000. NPC is ende-
mic in Southern China and North Africa1–3 and is thus most preva-
lent in The Netherlands among immigrants from high incidence
countries like China, Indonesia in Southeast Asia and North Africa
like Morocco.4
The World Health Organization (WHO) distinguishes three
major histological forms: keratinizing squamous cell carcinoma
(SCC) (WHO-I) – highly differentiated tumours with characteristicfax: +31 (0)10 70 38475.
old).
sevier OA license. epithelial cell shape, growth patterns and keratin ﬁlaments – as
well as differentiated (WHO-IIA) and undifferentiated (WHO-IIB)
non-keratinizing carcinoma, that retain epithelial cell shape and
growth patterns and are distinguished based on light
microscopy.5–7 While WHO-I is more common in low-incidence
populations, WHO-IIA and B usually occur more frequently in
high-incidence populations.8,9
A well-established risk factor for NPC is infection with Epstein-
Barr virus (EBV), an ubiquitous herpes virus and conﬁned to
non-keratinizing carcinomas (WHO-IIA and B). Tobacco smoking
and alcohol consumption are likely to contribute to SCCs of the
nasopharynx (WHO-I).10,11
Nasopharyngeal carcinoma is highly sensitive to radiotherapy,
the standard treatment for NPC patients without distant
metastases. Cases with more advanced disease usually receive
238 M. Arnold et al. / Oral Oncology 49 (2013) 237–243chemo-radiation.12 Important prognostic factors for survival are
stage, WHO type and age at diagnosis. Recently, EBV-related mark-
ers for diagnosis and prognosis of NPC became available13–16
including molecular deﬁned EBV (IgA) serology, which is charac-
teristic for undifferentiated carcinomas (WHO-IIB), detection of
EBV DNA load and oncogenic mRNA in nasopharyngeal brushings,
reﬂecting local tumour presence and EBV DNA load in blood
reﬂecting disease activity, clinical response after therapy and pre-
dicting distant metastases.17
The aim of this study was to assess progress against NPC by
investigating population- and behaviour-related trends in inci-
dence and tumour sub-classiﬁcation, together with survival and
mortality since 1970/1989 in The Netherlands, a low incidence
country.Materials and methods
Incidence data on NPC from 1989 to 2009 were extracted from
the population-based Netherlands Cancer Registry (NCR). Only
malignant tumours were included. Sarcomas in the nasopharynx
were excluded. Mortality data from 1970 to 2009 were acquired
from Statistics Netherlands which is based on attending doctors
ﬁlling in cause of death forms.18 Information on the vital status
of newly diagnosed cancer patients during 1989–2009 was initially
obtained from municipal registries and from 1995 onward from
the nationwide database of all municipal population registries,
providing virtually complete coverage of all deceased Dutch
citizens. Follow-up was complete until 1 January, 2010. For most
analyses, males and females were grouped and stratiﬁed into three
age groups (<60, 60–74 andP75 years). Three main histological
types according to the WHO classiﬁcation5 were distinguished:
keratinizing SCC (WHO-I) as well as differentiated (WHO-IIA) and
undifferentiated (WHO-IIB) non-keratinizing carcinoma. Neuro-
endocrine carcinoma, adenocarcinoma and tumours without path-
ological conﬁrmation were combined as ‘other carcinoma’. Stage
was registered according to the UICC TNM Classiﬁcation. Cases
diagnosed 1989–1998 were classiﬁed according to the 4th TNM
edition and diagnosed 1999–2009 according to later editions, as
those are equal for NPC. Additional information on country of birth,
not included in the original dataset, was provided in hindsight and
upon request from the NCR. It thus marginally deviates from the
patient group included in the original study but still represents a
valid comparison.
Incidence and mortality rates were standardized to the
European standard population. Changes in rates were evaluated
by calculating the estimated percentage of change (EAPC) and
the corresponding 95% Conﬁdence Interval (CI). This was done by
performing a linear regression analysis where a regression line is
ﬁtted to the natural logarithm of the rates, using calendar year as
regressor variable. The trend was considered signiﬁcant when the
p-value was below 0.05. Changes in NPC occurrence were identi-
ﬁed by performing joinpoint regression analysis (National Cancer
Institute, Bethesda, Maryland).19
One-, three- and ﬁve-year relative survival was used to estimate
disease-speciﬁc survival. Relative survival reﬂects the survival of
cancer patients, adjusted for competing causes of death in the
general population with the same age and gender distribution.
Traditional cohort-based relative survival analysis was performed
for the period 1989–2009. All statistical analyses were performed
using SAS (version 9.2).Results
The main characteristics of all 1411 patients diagnosed with
NPC between 1989 and 2009 are summarized in Table 1. Amongthe patients were 1005 (71%) males and 406 (29%) females. The
male-to-female incidence ratio, being 2.5 during 1989–1993,
gradually equalized in more recent years. About 59% of the
patients were below age 60 at diagnosis throughout the study
period.
During 1989–1998, only 11% of the cases were diagnosed in
stage I and II, and 14% in stage III and 69% in stage IV. Stage distri-
bution changed to 25% stage I and II, 29% stage III and 40% stage IV
since 1999.
With 621 cases (44%), undifferentiated non-keratinizing carci-
noma (WHO-IIB) was the predominant histological type, followed
by 555 (39%) keratinizing squamous cell carcinomas (WHO-I)
and 115 (8%) differentiated non-keratinizing carcinomas
(WHO-IIA). Radiotherapy was most commonly administered to
these patients. While 715 patients (51%) received radiotherapy
only, another 429 patients (30%) were treated in combination with
systemic and/or chemotherapy. Merely 76 patients (5%) received
additional surgery and in 99 patients (7%) treatment was aban-
doned. About 69% of all newly diagnosed NPC patients were born
in The Netherlands, 10% in Morocco, 5% in China, 4% in Indonesia
and 3% in Turkey.Histological variation
Patients with WHO-I tumours were on average older, diagnosed
at later stages and received surgery more often than patients with
other tumour histology. WHO-I was the predominant NPC type in
patients born in The Netherlands (47%), whereas in patients born
in most non-western countries, WHO-IIB was the most common
histological variant (53–66%; Table 1).Trends in incidence
Among males, the age-standardized incidence rate of NPC sig-
niﬁcantly decreased over time from 0.8 per 100,000 in 1991 to
0.5 in 2007 (EAPC 1989–2009: 1.3; 95% CI: 2.5, 0.2), whereas
the incidence among females remained stable at about 0.2 per
100,000 (Table 2, Fig. 1). The age-speciﬁc incidence rose after the
age of 30 and peaked at the age 55–65 years, being highest in the
period 1989–1991 (Fig. 2). A decline in incidence was observed
in almost all age groups, however only signiﬁcant in patients aged
75 and over (EAPC: 3.5; 95% CI: 6.3, 0.8). The incidence of
WHO-I tumours decreased signiﬁcantly between 1989 and 2009
(EAPC: 3.6; 95% CI: 5.3, 1.8), whereas the incidence of non-
keratinizing differentiated tumours signiﬁcantly increased in
males (EAPC: 6.6; 95% CI: 2.5, 10.8) (Table 2).Trends in survival
One- and three-year relative survival slightly increased and
amounted to 81% and 65% in 2009 as compared to 79% and 57%
in 1989, respectively (Fig. 3). Five-year relative survival rose from
50% in 1989–1993 to 55% in 2004–2009. No sex-speciﬁc
differences were found, but relative survival was clearly worse
for patients of higher age and stage. Whilst patients with non-
keratinizing tumours (WHO-IIA and B) had the highest survival
rates which slightly increased over time (1-year relative survival
ranging from 91% to 98%), survival of patients with keratinizing
SCCs (WHO-I) was lower (1-year relative survival ranging from
65% to 78%) and slightly decreased over time (Fig. 4). Similarly,
3-year relative survival increased in patients with non-keratinizing
tumours (ranging from 64% to 78%) and decreased in patients with
WHO type I tumours (ranging from 53% to 44%) (data not shown).
Table 1
Characteristics of incident NPC cases according to WHO histology classiﬁcation 1989–2009. Source: NCR.









n % n % n % n % n
Period of diagnosis
1989–1993 162 47 13 4 143 41 28 8 346
1994–1998 128 42 10 3 134 44 32 11 304
1999–2003 122 35 29 8 164 47 34 10 349
2004–2009 143 35 63 15 180 44 26 6 412
Age at diagnosis (yrs)
0–14 3 9 1 3 17 50 13 38 34
15–29 10 14 4 6 50 71 6 9 70
30–44 58 27 23 11 122 56 15 7 218
45–59 218 43 43 8 219 43 27 5 507
60–74 197 45 34 8 164 38 39 9 434
75+ 69 47 10 7 49 33 20 14 148
Sex
Male 412 41 82 8 451 45 60 6 1005
Female 143 35 33 8 170 42 60 15 406
Stage at diagnosis (1989–1999)
1 20 63 1 3 6 19 5 16 32
2 21 54 3 8 12 31 3 8 39
3 46 52 0 0 39 44 3 3 88
4 190 43 19 4 211 47 27 6 447
Unknown 13 30 0 0 9 20 22 50 44
Stage at diagnosis (1999–2009)
1 16 41 6 15 12 31 5 13 39
2B 48 32 19 13 78 52 4 3 149
3 69 31 32 14 113 51 7 3 221
4A 78 40 23 12 76 39 16 8 193
4B 31 44 7 10 32 45 1 1 71
4C 14 36 3 8 20 51 2 5 39
Unknown 9 18 2 4 13 27 25 51 49
Country of birth
Netherlands 444 47 72 8 364 38 70 7 950
Other Western 13 54 0 0 10 42 1 4 24
Indonesia 18 30 9 15 32 53 1 2 60
Suriname/Dutch Antilles 12 35 2 6 18 53 2 6 34
Turkey 17 40 1 2 24 57 0 0 42
Morocco 29 21 17 13 88 65 1 1 135
China 16 25 5 8 43 66 1 2 65
Other non-western 20 31 9 14 35 55 0 0 64
aData on country of birth originate from a separate dataset provided upon request by The Netherlands Cancer Registry.
Table 2
Trends in NPC incidence and mortality according to sex, age group, stage at diagnosis and histology in The Netherlands 1970/1989–2009.a Source: NCR, Statistics Netherlands
EAPC Incidence (1989–2009) Mortality (1970–2009) Mortality (1989–2009)
Males Females Total Males Females Total Males Females Total
Overall (95% CI) 1.3 1.0 1.2 1.5 0.5 1.2 3.7 1.3 3.0
(2.5,0.2) (3.2,1.3) (2.3,0.2) (2.2,0.8) (1.7,0.6) (1.8,0.5) (5.3,2.0) (4.6,2.1) (4.3,1.6)
Age < 60 0.9 1.7 1.0 1.5 0.4 1.1 2.2 2.6 2.4
(2.2,0.5) (4.7,1.4) (2.4,0.3) (2.3,0.6) (1.8,1.0) (1.8,0.5) (4.1,0.4) (6.5,1.4) (3.8,1.0)
Age 60–74 1.3 1.1 0.8 1.5 0.2 1.0 4.7 0.4 3.4
(3.2,0.7) (2.8,5.0) (2.7,1.1) (2.6,0.5) (2.0,1.6) (1.9,0.1) (6.9,2.4) (4.5,5.3) (5.4,1.4)
AgeP 75 3.4 3.0 3.5 1.3 3.1 1.6 3.0 0.8 3.2
(8.0,1.3) (7.8,1.7) (6.3,0.8) (2.6,0.1) (4.7,1.5) (3.0,0.2) (6.3,0.3) (3.1,4.7) (6.3,0.2)
WHO-I 3.2 3.7 3.6
(5.0,1.3) (6.7,0.7) (5.3,1.8)
WHO-IIA 6.6 3.0 9.6
(2.5,10.8) (8.5,14.5) (5.6,13.5)
WHO-IIB 0.7 0.5 0.7
(2.3,0.9) (2.7,1.8) (1.8,0.5)
EAPC = Estimated Annual Percentage Change; 95% CI = 95% Conﬁdence Interval.
a Bold numbers are signiﬁcant at p < 0.05 level.
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Figure 2 Age-speciﬁc NPC incidence per 100,000 person-years, 1989–2009. Source: NCR.
Figure 3 Trends in 1-, 3- and 5-year cohort-based relative survival from NPC, 1989–
2009. Source: NCR.
Figure 1 Three-year moving averages of age-standardized NPC incidence and mortality rates per 100,000 person-years (ESR) in The Netherlands 1970/1989–2009. Source:
NCR, Statistics Netherlands
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Between 1970 and 2009, 1275 persons died from NPC in The
Netherlands (683 between 1989 and 2009) as recorded by
Statistics Netherlands. The mortality-to-incidence ratio, anapproximation measure for survival,20 was thus 0.48 for the period
1989–2009. Most deaths (39%) occurred at age 60–74 years. About
41% of all deaths were younger than age 60 and 21% in patients
aged 75 and over.
Overall mortality from NPC signiﬁcantly decreased between
1970 and 2009 from 0.3 per 100,000 in 1971 to 0.1 per 100,000
in 2008 (EAPC 1970–2009: 1.2; 95% CI: 1.8, 0.5), however
even stronger since 1989 (EAPC: 3.0; 95% CI: 4.3, 1.6) (Table
2, Fig. 1). The decrease during the latter period was more
pronounced in males than in females and was observed across all
age groups, however particularly in females aged 75 and over
(Table 1).
Discussion
We found a decrease in NPC incidence, especially inmales and of
smoking related keratinizing SCC (WHO-I), coincidingwith a signif-
icant increase of differentiated non-keratinizing NPC (WHO-IIA).
The decline of cases with the poorest survival (WHO-I) in
combination with slowly improving survival rates led to markedly
decreasing mortality from NPC in The Netherlands in recent years,
implying real progress.
Between 1989 and 2009, age-standardized incidence of NPC de-
creased signiﬁcantly in males and a downward tendency was
also observed in females. According to ‘Cancer Incidence in Five
Figure 4 Trends in 1-year cohort-based relative survival from NPC by WHO
histology classiﬁcation, 1989–2009. Source: NCR.
M. Arnold et al. / Oral Oncology 49 (2013) 237–243 241Continents – volume VI, VIII and IX’ and the literature, NPC risk is
slowly decreasing in many European countries.1,2,21 There is a
marked South-North gradient in NPC risk with the highest rates
in Malta (Fig. 5). A similar study from Scotland22 only showed a
clear decline in males below age 50 coinciding with increased
NPC risks, also of dying, for people from lower socio-economic
backgrounds. Studies from China also conﬁrmed an inverse rela-
tionship of NPC incidence and social class.10 Worldwide, a bimodal
pattern in age-speciﬁc incidence curves of NPC was exhibited in
low-risk populations with a ﬁrst peak in late adolescence/early
adulthood (ages 15–24 years), a subsequent decline and a second
peak in later life (ages 65–79 years), but this was not evident in
high-risk populations.11 In our data, however, we could not con-
ﬁrm this pattern, possibly due to low numbers.
The observed trends in our study are most likely due to varia-
tion over time in exposure to carcinogenic risk factors as well as
to increasing immigration from high-incidence regions of NPC.
Even though the contribution of environmental, viral and genetic
risk factors in the causation of NPC has long been controversial,
the role of EBV in the development WHO-IIA and B tumours is
clearly established.23 The association between NPC risk, tobacco
smoking and alcohol drinking, however, seems to be conﬁned to
SSCs of the nasopharynx (WHO-I).24 More than two-thirds of dif-
ferentiated squamous cell NPC cases arising in older persons were
due to smoking and, to a lesser degree, to alcohol in a study from
the US.9 However, the role of alcohol in the causation of NPC is con-
sidered interactive with smoking.24 In our study, we found a higher
and increasing incidence of non-keratinizing tumours as opposed
to a lower and slowly decreasing incidence of (smoking-related)
keratinizing SCCs. Smoking in The Netherlands decreased from
59% in 1970 to 28% in 2009.25 Similarly, a decreasing incidence
in WHO-I tumours has been observed in high-incidence areas like
Southern China and Hong Kong in recent years and is most proba-
bly also due to the decline in smoking.26 In contrast, the increasing
incidence of non-keratinizing tumours suggests a driving role of
EBV and other environmental risk factors. The consumption of
salted ﬁsh and preserved foods may indeed play important etio-
logic roles.10
Earlier studies found that NPC incidence is particularly high in
migrants from high-incidence regions. For instance, a recent study
from Sweden revealed elevated risks for NPC among immigrants
from Former Yugoslavia, Asian Arab countries, Southeast Asia
and North Africa, being up to 35-fold the risk of native Swedes.27
Accordingly, the histological types of NPC varied by patient origin
in our study: whereas WHO-I was the predominant NPC type in
patients born in The Netherlands, it was WHO-IIB in patients born
in most non-western countries. This pattern has also been
described previously among Japanese and Chinese in comparisonwith Caucasian patients with NPC.28 Thus, the increase in the inci-
dence of EBV-related tumours (WHO-IIA and B) might be explained
by recent migration waves to The Netherlands, the number of
immigrants from China nearly tripling between 1996 (16,000)
and 2011 (45,000).18 Given the latest immigration ﬁgures and
assuming that most Chinese, South-East Asian and North-African
migrants carry higher NPC risks, especially for WHO-IIA and B
tumours, the observed trends in this study are in line with expec-
tations. This also implies that immigrant groups deserve special
attention from health care professionals with regard to NPC risk
and that EBV-based NPC diagnostics might be considered for
risk-assessment and treatment monitoring in this group.13–15 A
recent review on changes in NPC risk in Chinese after migration
to a low-risk country indicated decreasing risks the further the
population had migrated and the longer they had stayed.29 In view
of these results, it can be expected that NPC risks in migrants in
The Netherlands will slowly decrease and converge towards the
low rates in the general Dutch population.
In recent years, survival from NPC has increased steadily due to
earlier diagnosis and reﬁned staging and treatment in many other
countries30; more advanced technologies like intensity-modulated
radiation therapy (IMRT) have been quite instrumental. In addi-
tion, enhanced imaging of the nasopharyngeal region by magnetic
resonance imaging (MRI) instead of CT-imaging and adjustment of
radiotherapy doses have considerably reﬁned treatment options in
recent years. Five-year relative survival increased from 50% in
1989–1993 to 55% in 2004–2009 in our study, which is close to
48% found in 129 NPC patients diagnosed between 1977 and
1993 in The Netherlands.31 A Europe-wide study found even lower
NPC survival; 1- and 5-year relative survival rates were 75% and
34% for males and 72% and 32% for females, respectively.32 Clearly,
stage of disease at diagnosis and tumour histology and, to a lesser
extent, age at diagnosis determined the prognosis. As more than
two thirds of all newly diagnosed NPC cases are stage 3 or 4
tumours with a reduced chance for cure, this might be due to often
non-speciﬁc and ﬂu-like symptoms. In addition, low numbers of
cases seen by Dutch clinicians per year may limit their familiarity
with the diagnosis of NPC. Specialists in non-endemic regions, like
The Netherlands, are not very acquainted with the symptoms of
NPC and the number of migrants from the especially from North
Africa and South East Asia is not rising that rapidly. Substantial
doctor’s delay is also manifest among in health care workers in
high incidence regions like Indonesia where NPC is one of the most
common tumours.33
We found the poorest survival among patients with keratinizing
SCC (WHO-I), reﬂected by a higher proportional incidence of
locally advanced tumours and loco-regional failure, comparing
unfavourably with non-keratinizing tumours.16,34 As migrants of
non-western origin more often carry non-keratinizing tumours,
they probably have a better survival from NPC than native Dutch
patients.
Our results alsoemphasize theneed formore ‘tumour-customized’
treatment plans for different WHO types of NPC, in particular
WHO-I tumoursmay require amoreaggressiveor adjusted treatment.
Limitations
We explored the combined picture of NPC incidence, survival
and mortality, but the ﬁnal effect of declining incidence and
increasing survival since 1989 will only fully be reﬂected in
mortality in the next few years, even though NPC fatality is rather
high and mortality often occurs within few years after diagnosis.
However, NPC continues to be a rare disease and trends subject
to random variation, entailing difﬁcult interpretations. Besides,
changes in pathological practice in the classiﬁcation of NPC may
have contributed to the observed trends and made it impossible
Figure 5 Trends in NPC incidence in males (A) and females (B) in selected European countries according to Cancer Incidence in Five Continents, Volumes VI, VIII and IX (1–2).
For Volume VI, data from Volume III was used as substitute. For Volume IX, data for Portugal, Porto was used as substitute. For Volume VI, data from The Netherlands,
Eindhoven was used as substitute. §For Volume IX, data from the UK, East of England was used as substitute.
242 M. Arnold et al. / Oral Oncology 49 (2013) 237–243to investigate time trends according to stage. Although the correct
differentiation of WHO types has advanced in recent years, a small
degree of misclassiﬁcation cannot be ruled out.Conclusion
Since 1989, the incidence of NPC in The Netherlands decreased,
mainly of smoking-related, keratinizing NPC (WHO-I), coinciding
with an increase of non-keratinizing NPC (WHO-IIA and B) most
likely due to changes in the classiﬁcation of NPC tumours and
immigration of persons from high-incidence countries. The use of
EBV-related markers may improve detection of NPC in this group.
Mortality clearly decreased over time by the combination of a
decrease of the worse prognosis, smoking related WHO-I tumour
type and an increase of the better prognostic WHO II type
especially in males.Conﬂict of interest statement
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